Artrya (AYA) AGM 2026 summary

Opening remarks and agenda

• AGM held in person in West Perth with a live Zoom broadcast; voting was limited to in-person ballots and proxies, with questions accepted from the floor and in advance.

• Formal business covered seven resolutions; the proposed constitutional change was withdrawn and is planned to return at a future general meeting.

Financial performance review

• Cash of $67.2m and nil debt as at 30 September 2026; FY26 R&D rebate of $4.8m due.

• First U.S. revenue came from Salix Coronary Anatomy subscriptions and per-scan Salix Coronary Plaque fees; five commercial health systems had signed agreements, spanning 41 hospitals.

• HonorHealth’s agreement includes an AUD 0.5m platform subscription plus per-scan fees for plaque and, after clearance, flow; plaque scan volumes rose across the quarters to September 2026.

• The U.S. CCTA scan market was cited at US$4.4bn annually; CMS announced 2027 rates of US$395 for CCTA, US$950 for plaque assessment and US$850 for flow assessment.

Board and executive committee updates

• Jeff Le Benger and Helen Kurincic joined the board and stood for election at the AGM; Clayton Hatch commenced as CFO in September, bringing U.S. healthcare commercialization experience.

• A Chief People Officer and U.S. operations general manager were appointed; recruitment continued for experienced U.S. healthcare staff and a CTO.